指南与共识重症综合管理与镇静镇痛消化、代谢与肾脏急症

重症监护病房的抗菌药物耐药与抗菌药物管理项目:抗击耐药需坚持不懈——ESICM/ESCMID/WAAAR耐药圆桌会议立场声明

Antimicrobial resistance and antibiotic stewardship programs in the ICU: insistence and persistence in the fight against resistance. A position statement from ESICM/ESCMID/WAAAR round table on multi-drug resistance.
指南 / 共识 · Intensive Care Med · 2017-12-29
一句话结论ESICM/ESCMID/WAAAR联合声明:每个ICU都应优先开展抗菌药物管理项目并联合其他专科协作,以遏制耐药、改善耐药感染治疗并协调科研。

该立场声明由欧洲重症医学会、欧洲临床微生物与感染病学会及世界抗微生物耐药联盟的专家联合发布,组成ANTARCTICA联盟。声明指出抗菌药物耐药对全球任何ICU患者均构成明确而现实的威胁,ICU患者因治疗强度大、使用侵入性装置、传播风险增加及抗菌药物暴露而尤其高危;耐药存在地理差异且致病菌种类不同。声明呼吁提高认识并采取行动减少重症患者耐药发生、改善耐药感染治疗、协调该高危人群的科研,并将与其他专科密切协作及把这些干预纳入抗菌药物管理项目作为每个ICU的优先事项。

要点

  • 抗菌药物耐药对全球任何ICU患者均构成明确而现实的威胁,ICU患者因治疗强度、侵入性装置、传播风险及抗菌药物暴露而尤其高危。
  • 耐药存在于每个ICU,但患病率存在地理差异,所遇耐药致病菌种类可变。
  • ESICM、ESCMID与WAAAR专家组成ANTARCTICA联盟,呼吁医护人员提高认识并采取行动减少重症患者耐药发展。
  • 应将与其他专科密切协作及把这些干预纳入抗菌药物管理项目作为每个ICU的优先事项。
  • 合理使用抗菌药物并采取严格感染控制措施遏制耐药,是全体医护人员(从医生到维护人员、从护士到理疗师、从顾问到医学生)的共同责任。

适用人群与场景

  • 全球任何ICU的危重症患者;ICU患者因治疗强度大、使用侵入性装置、传播风险增加及抗菌药物暴露而尤其高危。

处置流程与药物剂量

  • 将与其他专科密切协作及把这些干预纳入抗菌药物管理项目作为每个ICU的优先事项。
  • 合理使用抗菌药物并采取严格感染控制措施以遏制耐药。

研究设计与关键结果

  • 制定机构为欧洲重症医学会(ESICM)、欧洲临床微生物与感染病学会(ESCMID)与 World Alliance Against Antimicrobial Resistance(WAAAR),组成ANTARCTICA联盟发布立场声明;原文未报告方法学与证据分级体系。

证据类型、等级与局限

  • 证据类型:学会联合立场声明;原文未报告证据等级或推荐强度。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 声明呼吁在每一ICU提高对耐药的认识并采取行动,以减少危重症患者耐药发展、改善耐药感染治疗并协调该高危人群的科研。
  • 作者认为应将与其他专科密切协作及把这些干预纳入抗菌药物管理项目作为每个ICU的优先事项。

指南或共识出处

  • ESICM/ESCMID/WAAAR round table on multi-drug resistance position statement: Antimicrobial resistance and antibiotic stewardship programs in the ICU: insistence and persistence in the fight against resistance(Intensive Care Med)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Antimicrobial resistance (AMR) is a clear and present danger to patients in any intensive care unit (ICU) around the world. Whereas AMR may affect any patient in the hospital, patients in the ICU are particularly at risk of acquiring AMR infections due to the intensity of the treatment, use of invasive devices, increased risk of transmission and exposure to antibiotics. AMR is present in every ICU, although prevalence is geographically different and AMR pathogens encountered are variable. Intensive care and infectious disease specialists from the European Society of Intensive Care Medicine, European Society of Microbiology and Infectious Diseases and World Alliance Against Antimicrobial Resistance, united in the ANTARCTICA (Antimicrobial Resistance in Critical Care) coalition, call for increased awareness and action among health care professionals to reduce AMR development in critically ill patients, to improve treatment of AMR infections and to coordinate scientific research in this high-risk patient population. Close collaboration with other specialties, and combining these and other interventions in antibiotic stewardship programmes should be a priority in every ICU. Considerate antibiotic use and adopting strict infection control practices to halt AMR remains a responsibility shared by all healthcare workers, from physicians to maintenance personnel, from nurses to physiotherapists, from consultants to medical students. Together, we can reduce AMR in our ICUs and continue to treat our patients effectively.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. De Waele JJ, Akova M, Antonelli M, et al. Antimicrobial resistance and antibiotic stewardship programs in the ICU: insistence and persistence in the fight against resistance. A position statement from ESICM/ESCMID/WAAAR round table on multi-drug resistance. Intensive Care Med. 2017. PMID: 29288367. doi:10.1007/s00134-017-5036-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。